Indefinite Delivery Contract SPE2DB24D9211

The Defense Logistics Agency (DLA) awarded DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business, a single-award indefinite delivery contract valued at up to $499,999,999 through December 31, 2025. This contract, under the SPE2DB program, enables DLA to issue firm fixed-price delivery orders for a broad range of pharmaceutical items including flumazenil injection, prednisone tablets, ampicillin injections, clotrimazole cream, epinephrine auto-injectors, and other branded and generic medications spanning various therapeutic classes. DMS Pharmaceutical Group, a leading pharmaceutical wholesaler, will fulfill the recurring medical supply needs of military health facilities supported by DLA worldwide. This IDV contract complements DMS Pharmaceutical Group's separate prime vendor contracts for direct distribution of prescription drugs and pharmacy services to Department of Defense sites.

The scope of the contract includes delivery of pharmaceutical products such as naltrexone tablets, botulinum toxin injections, contraceptive implants and intrauterine devices, chemotherapy drugs, HIV antiretrovirals, ophthalmic solutions, injectable anesthetics, and other branded and generic medications. DMS Pharmaceutical Group will leverage its expertise in pharmaceutical distribution and cold chain logistics to ensure timely and reliable supply of these critical medical products to support the healthcare needs of U.S. military personnel and their families globally.